Some of the content on this page has been created using generative AI.
What is it about?
The study compared the efficacy of SGLT2 inhibitors and other glucose-lowering drugs on kidney function in patients with type 2 diabetes mellitus and chronic kidney disease using a nationwide multicenter registry in Japan. The results showed that SGLT2 inhibitors were associated with a slower rate of estimated glomerular filtration rate decline and a lower risk of kidney outcomes compared to other glucose-lowering drugs. The benefits of SGLT2 inhibitors were consistent across subgroups, including those with or without proteinuria and different rates of eGFR decline. The study provides evidence that the benefits of SGLT2 inhibitors observed in clinical trials translate to patients treated in clinical practice.
Featured Image
Why is it important?
This research is important because it provides evidence that the benefits of SGLT2 inhibitors observed in clinical trials translate to patients treated in clinical practice, with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria. This study is clinically relevant since patients who have rapid decline in eGFR are at high risk for kidney failure within a short period. Key Takeaways: 1. SGLT2 inhibitors were associated with reduced eGFR decline and a lower risk of composite kidney outcomes among T2DM and CKD patients. 2. The benefits of SGLT2 inhibitors over other glucose-lowering drugs on change in eGFR were greater among patients who did not have rapid eGFR decline before initiating treatment and those who were using ACE inhibitors or ARBs at the index date. 3. Initiation of SGLT2 inhibitors versus other glucose-lowering drugs was associated with a significantly lower risk of a clinically important composite end point of a 50% eGFR decline or ESKD.
AI notice
Read the Original
This page is a summary of: Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database, Diabetes Care, October 2021, American Diabetes Association,
DOI: 10.2337/dc21-1081.
You can read the full text:
Contributors
The following have contributed to this page